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of cardiovascular disease compared to the general popu-
lation.1 Ischemic heart disease is the most common cause
of death in patients with chronic renal disease, and pa-
tients with acute coronary syndromes (ACS) usually suffer
from chronic renal disease.2,3 Furthermore chronic renal
disease is associated with poor survival in patients with
acute coronary syndrome with greater mortality and rein-
farction rates.4,5
The presence of chronic renal disease in patients with
ACS is common and is an independent unfavorable prog-
nostic factor. The National Cardiovascular Data Registry-
Acute Coronary Treatment and Intervention Outcomes
Network (NCDR-ACTION) registries indicated that 42.9% of
patients with NSTEMI and 30.5% of patients with STEMI have
chronic renal disease, defined as a GFR < 60 ml/min/
1.73 m2.6 Alternatively, acute renal failure in patients with
acute coronary syndromes has been studied less systemat-
ically. Most data come from retrospective studies, as the
presence of renal dysfunction is often a criterion for
exclusion from large prospective clinical trials.
Chronic kidney disease (CKD), defined as renal damage
of  3 months duration, characterized by structural or
functional abnormalities of the kidney with or without a
reduction in glomerular filtration rate (GFR). For the eval-
uation of renal function, several indicators are used as the
estimated glomerular filtration rate (GFR), based on
equations such as the MDRD equation or the Cockroft-Gault
equation, and the CKD-EPI.
Several mechanisms have been proposed regarding the
interaction between the heart and kidneys, where both
organs are affected when one of them suffers. This phe-
nomenon has been described as cardiorenal syndrome.7
Characteristics of this phenomenon are the residual con-
founding cardiovascular risk factors in patients with chronic
kidney disease, such as older age, diabetes, hypertension,
dyslipidemia, LV hypertrophy, hyperhomocysteinemia,
oxidative stress and high levels of inflammatory markers.
Additionally, complex interactions observed betweenPeer review under responsibility of Hellenic Cardiological
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calcium and phosphorus disorders, sodium and volume
overload, endothelial dysfunction due to uremia, oxidation
of LDL and oxidative stress by stimulating monocytes leads
to the proliferation of smooth muscle cells, accelerated
atherosclerosis, calcification of the coronary vessels,
remodeling of the left ventricle, reduced blood supply to
the coronary and systolic and diastolic dysfunction. On the
other hand, suboptimal therapy in patients with chronic
renal disease and acute coronary syndromes affect the
unfavorable prognosis. However, it is important to note
that patients with chronic kidney disease have a poor
prognosis, even when they receive the best treatment.
1. CKD and STEMI
Myocardial reperfusion seems to be used often in patients
with chronic kidney disease.8,9 Most studies are retrospec-
tive or registries. While there are a few prospective
reperfusion studies, chronic kidney disease is an exclusion
criterion. In patients with acute coronary syndromes, reg-
istries of large populations illustrate that short- and long-
term survival with early reperfusion is better compared to
drug therapy at all stages of renal disease.10 The indication
for angioplasty is preferable, with coated intracoronary
prosthesis (drug-eluting stent, DES) preferred over un-
coated (bare metal stent, BMS) because of a lower risk of
restenosis.11
Several studies have highlighted that STEMI patients
with chronic renal disease less frequently receive evidence-
based therapy compared to patients with normal renal
function, despite the evidence of superiority.12 In a study in
which the US Renal Data System database was matched
with the National Registry of Myocardial Infarction (NRMI),
patients on hemodialysis had more pre-hospital delays,
fewer recognized as suffering from AMI and less frequently
had ST-segment elevation or LBBB at baseline compared
with patients without dialysis. They also had higher mor-
tality. At discharge, CKD patients were less likely to receive
aspirin or beta-bockers.13 In the Global Registry of Acute
Coronary Events (GRACE) registry, the hospital mortalityElsevier B.V. This is an open access article under the CC BY-NC-ND
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4 or 5 chronic kidney disease. Both thrombolysis and pri-
mary angioplasty were associated with increased incidence
of bleeding complications in patients with severely
impaired renal function.4 Moreover, the progressive renal
dysfunction is a predictor of bleeding in patients receiving
anticoagulant therapy, which may be linked to both the
intrinsic renal impairment and antithrombotic failure or
avoidance of antithrombotics that are dependent on
excretion through renal dialysis.14
Additionally, acute renal failure in STEMI patients is
related to such factors as patient age, pre-hospital renal
function, medication, contrast volume and hemodynamic
state. Contrast nephropathy after coronary angiography
and intervention for STEMI is always a risk and requires
attention to both the volume of contrast and appropriate
hydration.15 In addition, patients may have other comor-
bidities resulting in increased risk of periprocedural
bleeding or ischemic events.2. Chronic Kidney Disease and NSTEMI
Based on the evaluation of renal function guidelines of
2015,16 it is necessary in all patients with NSTEMI to
perform an eGFR evaluation, especially in elderly women
with low weight. Patients with CKD are less likely to receive
the proper anticoagulant therapy and less likely reperfusion
therapy also.17
The diagnosis of NSTE-ACS in these patients presents
challenges because small variations of cardiac enzymes and
ECG changes are common. In most cases, increasing myo-
cardiac enzymes should not be attributed only to the
reduced creatinine clearance and considered “innocent”,
but instead a workup should be performed for cardiac
conditions such as chronic coronary artery disease or car-
diomyopathy of hypertension.18 Mainly in patients with
severe renal impairment (eGFR <30 mL/min/1.73 m2), it is
possible that an increased troponin can be due to renal
disease. The high-sensitivity troponin maintains a high
diagnostic value and clinical utility in patients with renal
dysfunction. Thus, the most likely diagnosis for a patient
with renal dysfunction and increased troponin is acute
myocardial infarction (45e80%).19
Prospectively, the effect of interventional therapy or
anticoagulant therapy has not been studied in patients with
renal impairment and NSTE-ACS. The SWEDEHAERT study
examined patients with kidney disease and NSTE-ACS and
showed that the more impaired the renal function of the
patient, the less likely the patient would undergo invasive
treatment and revascularization. Only 14% of patients with
an eGFR between 15e29 mL/min/1.73 m2 submitted for
interventional therapy.9 In a recent meta-analysis of
observational studies,20 it was recorded that early revas-
cularization therapy in patients with NSTE-ACS or unstable
angina leads to better survival in patients with mild or
moderate renal dysfunction. In patients with severe kidney
disease or dialysis or after renal transplantation, data were
missing, resulting in unclear data on whether early reper-
fusion therapy is the proper therapy.
In patients with chronic kidney disease, selection and
dosage of antithrombotic drugs must be carefully selected.While most anticoagulants need dosage adjustment, this is
not correct for the new oral antiplatelets.21 In patients with
end-stage renal disease (eGFR <15 mL/min/1.73 m2) the
data are incomplete. Therefore, the antiplatelet P2Y12
inhibitors used in high-risk patients for the prevention of
thrombosis should be used with caution in patients with a
bleeding risk. Clopidogrel exhibits a better safety profile
compared with ticagrelor or prasugrel. Several anticoagu-
lants are available for parenteral use, such as eptifibatide,
tirofiban, bivalirudin, enoxaparin and fondaparinux. Most of
them require adjustment for renal function. Regarding
abciximab, no adjustment is required, but in stage 4 kidney
disease the risks and benefits should be taken into account.
Corresponding adjustments for renal function are required
in newer anticoagulants.
3. Acute Renal Failure and ACS
In contrast to CKD, the available data on the effect of acute
renal failure (absolute increase 0.3 mg/dL, 50% increase
in baseline serum creatinine (1.5 times) in a 48 hour period
or reduction in urine output with documented oliguria
(<0.5 ml/kg per hour for> 6 hours)) in the clinical setting
of acute coronary syndromes are limited.
The incidence of acute renal failure is increasing in pa-
tients with acute coronary syndromes.22 This situation
presents a complex pathogenesis, has an incidence of over
30% and is associated with higher short- and long-term
morbidity and mortality. Acute renal failure precedes
renal failure as an index for disease severity, and it also
constitutes a causative factor for acceleration of cardio-
vascular damage by neurohormonal activation, immune and
inflammatory pathways. Recent data suggest that patients
with acute renal failure after acute coronary syndrome,
even those with fully recovered renal function, are at
increased risk of future acute injury and the development
of chronic kidney disease. Therefore, these patients
require both regular renal monitoring after hospital
discharge and secondary prevention measures.
4. Contrast Agent Nephropathy
Contrast agent nephropathy is defined as an increase in
serum creatinine of 0.5 mg/dL or 25% within 48e72
hours after exposure to the contrast agent. It is the main
cause of acute renal failure after catheterization in pa-
tients with acute coronary syndromes. Risk factors are age,
pre-existing renal disease, diabetes mellitus, cardiogenic
shock/cardiac insufficiency, anemia and the volume and
type of contrast. Prevention, especially in patients with a
GFR <40 mL/min/1.73 m2, requires the administration of
isotonic saline 12 hours before and 24 hours after angiog-
raphy in order to reduce the risk of kidney disease. How-
ever, caution must be exercised in fluid administration to
patients with heart failure. In addition, administration of
high dosages of statins before diagnostic catheterization is
a preventive measure in patients without contraindica-
tions. Finally, the use of other agents, such as ascorbic
acid, have shown inconsistent results, while the effect of N-
acetylcysteine is undisputed. Particularly important is the
role of minimization of the volume of contrast to <4 ml/kg.
212 President’s pageAdditionally, it seems that isosmotic agents are preferred
over low-osmolality contrast agents. Furthermore, the risk
for kidney disease greatly increases when the ratio of the
contrast volume to GFR is> 3.7:1.23,24
5. Conclusions
 Chronic kidney disease is a powerful risk factor for death
in acute coronary syndromes and affects clinical
decisions.
 It is important to identify the baseline serum creatinine
with ACS patients and monitor the course of renal
function during hospitalization.
 Beware of contrast nephropathy and use preventive
measures.
 Encourage the use of more aggressive therapies when
they can be implemented at an acceptable level of
safety.
 There is a need for randomized prospective clinical
studies evaluating the therapeutic strategies in these
patients.
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